• Clinical evaluation of the efficacy of new drugs and new treatment approaches for gliomas and meningiomas (Jordi Bruna, Miguel Gil, Ana Lucas, Miquel Macià, Carles Majós)
    • Chemotherapy-induced peripheral neuropathies (Jordi Bruna, Roser Velasco)
    • Cancer and cognition (Marta Simó)
    • Leptomeningeal metastases (Jordi Bruna, Miguel Gil)
    • Survival prognostic factors involved in central nervous system tumours (Noemí Vidal, Jordi Bruna, Carles Majós)
    • Prevention and personalised treatment of brain metastases: development of new therapies based on the prevention and prognosis of biomarkers (Miguel Gil, Noemí Vidal, Gerard Plans, Ana Lucas)

Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases

Ponce S., Bruna J., Juan O., López R., Navarro A., Ortega A., Puente J., Verger E., Bartolomé A., Nadal E.

2019

Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment

Psimaras D, Velasco R, Birzu C, Tamburin S, Lustberg M, Bruna J, Argyriou AA

2019

Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity

Cavaletti G, Cornblath DR, Merkies ISJ, Postma TJ, Rossi E, Alberti P, Bruna J, Argyriou AA, Briani C, Velasco R, Kalofonos HP, Psimaras D, Ricard D, Pace A, Faber CG, Lalisang RI, Brandsma D, Koeppen S, Kerrigan S, Schenone A, Grisold W, Mazzeo A, Padua L, Dorsey SG, Penas-Prado M, Valsecchi MG, CI-PeriNomS Group

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. (ISSN/ISBN: 10859489).

2019

[Radiation-induced cognitive toxicity in adults]

Cayuela N, Simo M

REVISTA DE NEUROLOGIA. (ISSN/ISBN: 02100010). 68(4): 160-168

2019

Neurooncología: por una subespecialidad transversal y colaborativa

Jordi Bruna Escuer, J. Pardo-Moreno

REVISTA DE NEUROLOGIA. (ISSN/ISBN: 02100010). 68(4): 135-136-

2019

Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age

Castet F, Alanya E, Vidal N, Izquierdo C, Mesia C, Ducray F, Gil-Gil M, Bruna J

2019

Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings

Argyriou AA, Park SB, Islam B, Tamburin S, Velasco R, Alberti P, Bruna J, Psimaras D, Cavaletti G, Cornblath DR, Toxic Neuropathy Consortium (TNC)

2019

Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations

Izquierdo C, Barritault M, Poncet D, Cartalat S, Joubert B, Bruna J, Jouanneau E, Guyotat J, Vasiljevic A, Fenouil T, Berthezène Y, Honnorat J, Meyronet D, Ducray F

NEUROSURGERY. (ISSN/ISBN: 0148396X).

2019

Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity

Argyriou AA, Bruna J, Anastopoulou GG, Velasco R, Litsardopoulos P, Kalofonos HP

2019

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer (Oncotarget (2018) 9 (27074-27086) DOI: 10.18632/oncotarget.25478)

Morán T, Felip E, Bosch-Barrera J, De Aguirre I, Ramirez J, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta C, Queralt C, Velarde J, Rosell R

2018

See full list

Cáncer de pulmón y toxicidad cognitiva: marcadores serológicos y de neuroimagen de disrupción de la barrera hemato-encefálica

Simo Parra, Marta (Investigador principal (IP))

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2019-01-01 - 2021-12-31

CONTRATOS PARA LA INTENSIFICACION DE LA ACTIVIDAD INVESTIGADORA EN EL SNS

Bruna Escuer, Jordi (Investigador principal (IP))

Ref.: INT16/00219

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2017-01-01 - 2017-04-07

Toxicitat cognitiva induïda per la quimioteràpia en pacients amb càncer de pulmó

Simo Parra, Marta (Participante)

CONTRATOS JUAN RODES

Simo Parra, Marta (Investigador principal (IP))

Ref.: JR15/00027

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2016-01-04 - 2019-01-03

An observational retrosepctive cohort study to evaluate the progression-free survival and overall survival at patients who participated in the SIGM-202 clinical trial

Simo Parra, Marta (Participante)

Entitat finançadora:
  • LABORATORIOS DR. ESTEVE, S.A.

Estudio exploratorio sobre la etiopatogenia, biomarcadores de riesgo y mecanismos implicados en la regeneración de la neuropatía inducida por platinos

Bruna Escuer, Jordi (Investigador principal (IP))

Ref.: PI15/01303

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2016-01-01 - 2018-12-31

Posible utilidad de la resonancia magnética preradioterapia precos (PRMR) para el seguimiento de los gliomas de alto grado

MAJOS TORRO, CARLOS (Investigador principal (IP))

Ref.: PR309/12

Entitat finançadora:
  • GEINO

2013-04-01 - 2016-03-31

Neurocognitive function sub-study of BO21990: A randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and radiotherapy followed by placebo and temozolomide in patients with newly diagnosed glioblastoma

Simo Parra, Marta (Investigador/a)

Entitat finançadora:
  • ROCHE FARMA, S.A.

A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer. NCT01657799

Simo Parra, Marta (Investigador/a)

Entitat finançadora:
  • ABBOTT CIENTÍFICA, S.A.

Ensayo prospectivo multicéntrico de NovoTTF-100A en combinación con temozolomida comparado con temozolomida en monoterapia en pacientes con GBM de reciente diagnóstico

Simo Parra, Marta (Investigador/a)

Entitat finançadora:
  • NOVOCURE LTD
See full list

Identification of clinical, neurophysiological and serum risk markers in chemotherapy-induced peripheral neuropathy

Bruna Escuer, Jordi (Director) Doctorando: Roser velasco

2017

Effects of chemotherapy and cranial radiation in brain structures and cognitive functions of lung cancer patients

Bruna Escuer, Jordi (Director) Doctorando: Marta Simo Parra; Rodriguez Fornells, Antoni (Director) Doctorando: Marta Simo Parra

2015

See full list

METHOD FOR DETERMINING THE RISK OF DEVELOPING BRAIN METASTASIS, AND A KIT TO CARRY OUT SAID METHOD

Sanz Pamplona, Rebeca (Inventores-as/autores-as/obtentores-as); SIERRA JIMENEZ, Angels (Inventores-as/autores-as/obtentores-as); OLIVA MIGUEL, Baldomero (Inventores-as/autores-as/obtentores-as); Moreno Aguado, Victor Raul (Inventores-as/autores-as/obtentores-as); Gil Gil, Juan Miguel (Inventores-as/autores-as/obtentores-as)

See full list

  • Identification of markers of clinical and neurophysiological predictive risk for developing oxaliplatin-induced neuropathy.
  • New demonstrations on the efficacy of the new sigma-1 receptor antagonist in preventing acute oxaliplatin-induced neuropathy in a randomised, phase 2 study.
  • Documentation of longitudinal brain changes associated with prophylactic cranial irradiation and chemotherapy in patients with small-cell lung cancer.
  • Identification of a common feature in glioblastomas: intrinsic deficiency of the DFF40/CAD endonuclease which affects DNA hydrolysis during caspase-dependent cell death.